Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 75, Issue 4, 2012, Pages 232-241

  Ellison, Corie A ^a   Abou El Ella, Soheir S ^b   Tawfik, Maha ^b   Lein, Pamela J ^c,d   Olson, James R ^a,e  

^a UNIVERSITY AT BUFFALO   (United States)

^b MENOUFIA UNIVERSITY   (Egypt)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPYRIFOS; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; DNA; EFAVIRENZ; IMMUNOSUPPRESSIVE AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PESTICIDE;

ADULT; AGRICULTURAL WORKER; ALLELE; ARTICLE; DEPRESSION; DIZZINESS; DNA DETERMINATION; DRUG METABOLISM; EGYPT; ENZYME ACTIVITY; ETHNIC GROUP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER MICROSOME; MAJOR CLINICAL STUDY; OCCUPATIONAL EXPOSURE; PESTICIDE SPRAYING; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SALIVA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; TOXICOKINETICS;

ADOLESCENT; ADULT; AGED; AGRICULTURE; ARYL HYDROCARBON HYDROXYLASES; CHLORPYRIFOS; COHORT STUDIES; EGYPT; GENE FREQUENCY; GENETIC MARKERS; GENOTYPE; HUMANS; INSECTICIDES; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; OCCUPATIONAL EXPOSURE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, SINGLE NUCLEOTIDE; SALIVA; YOUNG ADULT;

EID: 84858053103     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2012.641201     Document Type: Article

References (48)

1. Abdel Rasoul, G. M., M. E. Abou Salem, A. A. Mechael, O. M. Hendy, D. S. Rohlman, and A. A. Ismail. 2008. Effects of occupational pesticide exposure on children applying pesticides. Neurotoxicology 29: 833-38.
2. Andersson, T., C. G. Regardh, Y. C. Lou, Y. Zhang, M. L. Dahl, and L. Bertilsson. 1992. Polymorphic hydroxylation of Smephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2: 25-31.
3. Ariyoshi, N., M. Ohara, M. Kaneko, S. Afuso, T. Kumamoto, H. Nakamura, I. Ishii, T. Ishikawa, and M. Kitada. 2011. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab. Dispos. 39:2045-2048.
4. Atterberry, T. T., W. T. Burnett, and J. E. Chambers. 1997. Age-related differences in parathion and chlorpyrifos toxicity in male rats: Target and nontarget esterase sensitivity and cytochrome P450-mediated metabolism. Toxicol. Appl. Pharmacol. 147: 411-18. (Pubitemid 28062758)
5. Blaisdell, J., H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter, B. Chanas, T. Xi, B. Ghanayem, and J. A. Goldstein. 2002. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12: 703-11. (Pubitemid 36054937)
6. Bozina, N., V. Bradamante, and M. Lovric. 2009. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arch. Higij. Rada Toksikol. 60: 217-42.
7. Chang, T. K., G. F. Weber, C. L. Crespi, and D. J. Waxman. 1993. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53: 5629-37. (Pubitemid 23360263)
8. Cho, J. Y., H. S. Lim, J. Y. Chung, K. S. Yu, J. R. Kim, S. G. Shin, and I. J. Jang. 2004. Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab. Dispos. 32: 1341-44.
9. Clegg, D. J., and M. van Gemert. 1999. Expert panel report of human studies on chlorpyrifos and/or other organophosphate exposures. J. Toxicol. Environ. Health B 2: 257-79. (Pubitemid 30054872)
10. Cole, D. C., F. Carpio, J. Julian, and N. Leon. 1998. Assessment of peripheral nerve function in an Ecuadorian rural population exposed to pesticides. J. Toxicol. Environ. Health A 55: 77-91. (Pubitemid 28461392)
11. Crettol, S., J. J. Deglon, J. Besson, M. Croquette- Krokkar, I. Gothuey, R. Hammig,M. Monnat, H. Huttemann, P. Baumann, and C. B. Eap. 2005. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78: 593-604. (Pubitemid 41773635)
12. Croom, E. L., A. D. Wallace, and E. Hodgson. 2010. Human variation in CYP-specific chlorpyrifos metabolism. Toxicology 276: 184-91.
13. Daniel, H. I., and T. I. Edeki. 1996. Genetic polymorphism of S-mephenytoin 4′- hydroxylation. Psychopharmacol. Bull. 32: 219-30.
14. Demorais, S. M. F., G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. 1994. The major genetic-defect responsible for the polymorphism of Smephenytoin metabolism in humans. J. Biol. Chem. 269: 15419-22.
15. Desta, Z., T. Saussele, B. Ward, J. Blievernicht, L. Li, K. Klein, D. A. Flockhart, and U. M. Zanger. 2007. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8: 547-58. (Pubitemid 46947859)
16. Ellison, C. A., Y. Tian, J. B. Knaak, P. J. Kostyniak, and J. R. Olson. 2011. Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon. Drug Metab. Dispos., in press.
17. Farahat, F. M., C. A. Ellison, M. R. Bonner, B. P. McGarrigle, A. L. Crane, R. A. Fenske, M. R. Lasarev, D. S. Rohlman, W. K. Anger, P. J. Lein, and J. R. Olson. 2011. Biomarkers of chlorpyrifos exposure and effect in egyptian cotton field workers. Environ. Health Perspect. 119: 801-6.
18. Farahat, F. M., R. A. Fenske, J. R. Olson, K. Galvin, M. R. Bonner, D. S. Rohlman, T. M. Farahat, P. J. Lein, and W. K. Anger. 2010. Chlorpyrifos exposures in Egyptian cotton field workers. Neurotoxicology 31: 297-304.
19. Farahat, T. M., G. M. Abdelrasoul, M. M. Amr, M. M. Shebl, F. M. Farahat, and W. K. Anger. 2003. Neurobehavioural effects among workers occupationally exposed to organophosphorous pesticides. Occup. Environ. Med. 60: 279-86. (Pubitemid 36408252)
20. Foxenberg, R. J., C. A. Ellison, J. B. Knaak, C. Ma, and J. R. Olson. 2011. CytochromeP450-specific human PBPK/PD models for the organophosphorus pesticides: Chlorpyrifos and parathion. Toxicology 285: 57-66.
21. Foxenberg, R. J., B. P. McGarrigle, J. B. Knaak, P. J. Kostyniak, and J. R. Olson. 2007. Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos. Drug Metab. Dispos. 35: 189-93. (Pubitemid 46148729)
22. Galetin, A., and J. B. Houston. 2006. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J. Pharmacol. Exp. Ther. 318: 1220-29. (Pubitemid 44268329)
23. Goldstein, J. A., T. Ishizaki, K. Chiba, S. M. de Morais, D. Bell, P. M. Krahn, and D. A. Evans. 1997. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7: 59-64. (Pubitemid 27153320)
24. Griese, E. U., F. Lapple, and M. Eichelbaum. 1999. Detection of CYP2C19 alleles*1,*2 and*3 by multiplex polymerase chain reaction. Pharmacogenetics 9: 389-91. (Pubitemid 29376383)
25. Guan, S., M. Huang, E. Chan, X. Chen, W. Duan, and S. F. Zhou. 2006. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur. J. Pharm. Sci. 29: 14-21. (Pubitemid 44279393)
26. Haas, D. W., H. J. Ribaudo, R. B. Kim, C. Tierney, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, T. Hulgan, C. Marzolini, and E. P. Acosta. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18: 2391-400. (Pubitemid 40065906)
27. Hamdy, S. I., M. Hiratsuka, K. Narahara, M. El-Enany, N. Moursi, M. S. Ahmed, and M. Mizugaki. 2002. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 53: 596-603. (Pubitemid 34621785)
28. Herrlin, K., A. Y. Massele, M. Jande, C. Alm, G. Tybring, Y. A. Abdi, A. Wennerholm, I. Johansson, M. L. Dahl, L. Bertilsson, and L. L. Gustafsson. 1998. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther. 64: 391-401. (Pubitemid 28473765)
29. Jacob, R. M., E. C. Johnstone, M. J. Neville, and R. T. Walton. 2004. Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin. Chem. 50: 1372-77. (Pubitemid 38970644)
30. Jinno, H., T. Tanaka-Kagawa, A. Ohno, Y. Makino, E. Matsushima, N. Hanioka, and M. Ando. 2003. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31: 398-403. (Pubitemid 36378517)
31. Klein, K., T. Lang, T. Saussele, E. Barbosa-Sicard, W. H. Schunck, M. Eichelbaum, M. Schwab, and U. M. Zanger. 2005. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genom. 15: 861-73. (Pubitemid 41666768)
32. Kudzi, W., A. N. Dodoo, and J. J. Mills. 2009. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med. Genet. 10: 124.
33. Lang, T., K. Klein, J. Fischer, A. K. Nussler, P. Neuhaus, U. Hofmann, M. Eichelbaum, M. Schwab, and U. M. Zanger. 2001. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11: 399-415. (Pubitemid 32656581)
34. Ma, T., and J. E. Chambers. 1994. Kinetic parameters of desulfuration and dearylation of parathion and chlorpyrifos by rat liver microsomes. Food Chem. Toxicol. 32: 763-67. (Pubitemid 24268006)
35. Marzolini, C., A. Telenti, L. A. Decosterd, G. Greub, J. Biollaz, and T. Buclin. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15: 71-75. (Pubitemid 32055781)
36. Masimirembwa, C., L. Bertilsson, I. Johansson, J. A. Hasler, and M. Ingelman-Sundberg. 1995. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochromeP450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther. 57: 656-61.
37. Mehlotra, R. K., M. N. Ziats, M. J. Bockarie, and P. A. Zimmerman. 2006. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur. J. Clin. Pharmacol. 62: 267-75.
38. Nakajima, M., S. Komagata, Y. Fujiki, Y. Kanada, H. Ebi, K. Itoh, H. Mukai, T. Yokoi, and H. Minami. 2007. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genomics 17: 431-45. (Pubitemid 46763388)
39. Persson, I., E. Aklillu, F. Rodrigues, L. Bertilsson, and M. Ingelman-Sundberg. 1996. SMephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6: 521-26. (Pubitemid 27032304)
40. Povey, A. C. 2010. Gene-environmental interactions and organophosphate toxicity. Toxicology 278: 294-304.
41. Povey, A. C., F. Jury, W. M. Dippnall, A. E. Smith, S. Thomson, B. Mackness, M. Mackness, P. Durrington, and N. M. Cherry. 2007. GST CYP and PON1 polymorphisms in farmers attributing ill health to organophosphate-containing sheep dip. Biomarkers 12: 188-202. (Pubitemid 47161399)
42. Ribaudo, H. J., D. W. Haas, C. Tierney, R. B. Kim, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, C. Marzolini, C. V. Fletcher, K. T. Tashima, D. R. Kuritzkes, and E. P. Acosta. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. 42: 401-7. (Pubitemid 43122320)
43. Rose, R. L., J. Tang, J. Choi, Y. Cao, A. Usmani, N. Cherrington, and E. Hodgson. 2005. Pesticide metabolism in humans, including polymorphisms. Scand. J. Work Environ. Health 31(suppl. 1): 156-63; discussion 119-22.
44. Svensson, U. S., and M. Ashton. 1999. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br. J. Clin. Pharmacol. 48: 528-35. (Pubitemid 29454233)
45. Ward, B. A., J. C. Gorski, D. R. Jones, S. D. Hall, D. A. Flockhart, and Z. Desta. 2003. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306: 287-300. (Pubitemid 36734384)
46. Xie, H., L. Griskevicius, L. Stahle, Z. Hassan, U. Yasar, A. Rane, U. Broberg, E. Kimby, and M. Hassan. 2006. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci. 27: 54-61. (Pubitemid 41728255)
47. Xie, H. J., U. Yasar, S. Lundgren, L. Griskevicius, Y. Terelius, M. Hassan, and A. Rane. 2003. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 3: 53-61. (Pubitemid 36432466)
48. Zanger, U. M., K. Klein, T. Saussele, J. Blievernicht, M. H. Hofmann, and M. Schwab. 2007. Polymorphic CYP2B6: Molecular mechanisms and emerging clinical significance. Pharmacogenomics 8: 743-59. (Pubitemid 47288975)